Melanie Pointer, MD
Child & Adolescent Psychiatry · Atlanta, GANPI 1275736902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2019 at $289 and has fallen 93.5% since, to $19 in 2024.
Across 36 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250
- Takeda Pharmaceuticals U.S.A., Inc.$99
- Lundbeck LLC$60
- Shire North American Group Inc$51
- Sunovion Pharmaceuticals Inc.$47
- Supernus Pharmaceuticals, Inc.$34
- plus $127 from 6 others
What the payments were for
- Food & beverage$669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Lundbeck LLC | 3 | $60 |
| Shire North American Group Inc | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Corium, LLC | 1 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Viiv Healthcare Company | 1 | $19 |
| Neos Therapeutics, LP | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
How this compares
$669 in reported general payments places this provider in the 55th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 47 | $135,067 |
| VraylarCariprazine Hcl | 12 | $19,085 |
| Paliperidone ErPaliperidone | 21 | $2,145 |
| Clozapine | 23 | $1,827 |
| Aripiprazole | 14 | $1,654 |
| Olanzapine | 80 | $1,527 |
| Benztropine Mesylate | 105 | $1,250 |
| Trazodone Hcl | 127 | $1,186 |
| Quetiapine Fumarate | 57 | $1,149 |
| Olanzapine OdtOlanzapine | 11 | $1,127 |
| Thiothixene | 12 | $967 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $948 |
| Risperidone | 94 | $930 |
| Vilazodone Hcl | 14 | $924 |
| Carbamazepine | 37 | $850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $17 | $135,06747 claims |
| AbbVieVraylar | $250 | $19,08512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Atlanta
- Suneel KatragaddaAtlanta$460K
- Olujimi AdefisanAtlanta$14K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Douglas ChanAtlanta$4K
- Jane LanierAtlanta$3K
- Satyanarayana GedelaAtlanta$3K
- Ericka GoodwinAtlanta$1K
- Kerry SheahanAtlanta$1K
- Debora JohnsonAtlanta$695
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.